Sign Up Now
Watch the best videos collected by Libby's H*O*P*E* (tm).
Join 49 others following Libby's H*O*P*E* (tm)'s collection of 851 videos. It's free to sign up.
Libby's H*O*P*E* (tm)
Libby's H*O*P*E* - An on-line resource dedicated to the support of ovarian cancer survivors and their families through various on-line medical and education resources based upon the principle that "information is power." The empowerment of all ovarian cancer survivors through educational awareness allows them to persevere in their fight against ovarian cancer and proactively choose hope.
851 Videos
Member since May 1, 2008
Twitter @libbyshope
http://healthinfoispower.word...
http://twitter.com/libbyshope
Collections
Statistics
| 851 | Videos |
| Monthly Views |
Top Tags
-
Ovarian Cancer and Avastin® (Bevacizumab) - "WORDs Of Wisdom" Dr. Bradley J. Monk
"WORDs of Wisdom" video series: Dr. Bradley J. Monk explains the advantages and differences Avastin® has vs. other Ovarian Cancer treatment drugs, and how ovarian cancer patients may be able to access this treatment.Produced by: WORDonCancer.org (27 Jul 11)Collected in Libby's H*O*P*E* Aug 16, 2011 -
2011 ASCO: Standard of care for ovarian cancer - Prof. Stan Kaye
Prof. Stan Kaye discusses ovarian cancer developments discussed at the 2011 ASCO Annual Meeting, including: neo-adjuvant chemo, intraperitoneal chemo, bevacizumab (Avastin), PARP inhibitors, trabectedin, pegylated liposomal doxorubicin, EC-145, and immunotherapy. (23 Jun. 11)Collected in Libby's H*O*P*E* Jun 23, 2011 -
ASCO 2011: Ovarian cancer developments - Prof. Eric Pujade-Lauraine
Prof. Eric Pujade-Lauraine discusses numerous options for ovarian cancer, including bevacizumab (Avastin), PARP inhibitors, neo-adjuvant chemo, tradbectedin (Yondelis), and immunotherapy. (23 Jun. 11)Collected in Libby's H*O*P*E* Jun 23, 2011 -
2011 ASCO Annual Meeting - June 5th Highlights (incl. ovarian cancer)
The video covers several ovarian cancer topics highlighted on June 5 at the ASCO Annual Meeting, including ovarian cancer subtype classification, PARP inhibitors (olaparib & iniparib), Avastin phase 3 trial data (ICON7 & OCEANS). (06 Jun 11)Collected in Libby's H*O*P*E* Jun 6, 2011 -
ASCO 2011: "OCEANS" Phase 3 Avastin Trial Results
This ASCO virtual meeting video clip discusses results from the phase 3 clinical study of Avastin (bevacizumab) in newly diagnosed ovarian cancer patients. These results were recently presented at the 2011 ASCO Annual Meeting. (06 Jun 11)Collected in Libby's H*O*P*E* Jun 6, 2011 -
2011 ASCO: Avastin Data From OCEANS & ICON7 Clinical Studies
Dr. Andrew Seidman M.D., Memorial Sloan-Kettering Cancer Center, discusses results from two Avastin phase 3 studies (OCEANS & ICON7) relevant to treatment of ovarian cancer, as presented at the 2011 American Society of Clinical Oncology Annual Meeting.Collected in Libby's H*O*P*E* Jun 5, 2011 -
ASCO 2011 - Advances in Women's Cancers - Cancer.Net
Studies detailing new advances against women’s cancers (including ovarian) were released today at a press briefing at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO). The video addresses results from the ICON7 and OCEANS phase III Avastin trials. (04 Jun 11)Collected in Libby's H*O*P*E* Jun 4, 2011 -
Avastin Phase III Trials (GOG218, ICON7, OCEANS) - WORD of HOPE Ovarian Cancer Postcast
This video addresses preliminary data from the recent Phase III Avastin clinical trials which are testing the drug in newly-diagnosed and recurrent ovarian cancer patients. It is the first episode in a podcast series entitled, "10 Exciting 2010 Ovarian Cancer Research Topics." The series is co-hosted by Nate Manahan, WORD Executive Director, and Paul Cacciatore, founder of Libby's H*O*P*E*. Visit www.wordofhopepodcast.com.Collected in Libby's H*O*P*E* Mar 25, 2011 -
Dr. Tew Evaluates Bevacizumab (Avastin) Treatment in Ovarian Cancer
William P. Tew, M.D., a gynecologic medical oncologist at Memorial Sloan-Kettering Cancer Center, evaluates bevacizumab (Avastin) as a potential standard of care drug in the treatment of ovarian cancer. (24 Mar. 11)Collected in Libby's H*O*P*E* Mar 24, 2011 -
Cost-Effectiveness of Ovarian Cancer Drug Bevacizumab
An analysis conducted by Ohio State University cancer researchers has found that adding the targeted therapy bevacizumab (Avastin) to the treatment of patients with advanced ovarian cancer may not be cost effective. (09 Mar. 11)Collected in Libby's H*O*P*E* Mar 9, 2011 -
The role of bevacizumab in the treatment of ovarian cancer - ecancer tv.
Drs. Amit Oza (Princess Margaret Hospital, Toronto, Canada), Robert Burger (Fox Chase Cancer Center, Philadelphia PA, USA), Nicoletta Colombo ( European Institute of Oncology, Milan, Italy) discuss the results from the GOG 218 & ICON7 clinical trials involving bevacizumab use in ovarian cancer patients. (07 Feb. 11)Collected in Libby's H*O*P*E* Feb 7, 2011 -
Bevacizumab as part of standard first line treatment of ovarian cancer
Prof. Jonathan Ledermann talks about the possibility of using bevacizumab in the first line treatment of ovarian cancer. Research presented at ESMO 2010 in addition to previous research presented at ASCO 2010 demonstrated that the addition of bevacizumab to standard chemotherapy prolongs progression free survival. Aspects such as cost effectiveness, data reliability and likely effect on overall survival were debated at the ESMO congress and the majority of participants concluded that there was not yet enougCollected in Libby's H*O*P*E* Nov 10, 2010 -
ESMO 2010: GOG-218: Bevacizumab plus standard chemo for ovarian cancer
Dr. Rob Coleman, UT M.D. Anderson Cancer Ctr., speaks about the GOG-218 study which evaluates the effect of adding bevacizumab to standard carboplatin and paclitaxel therapy in patients with advanced ovarian cancer. Dr. Coleman explains about the differences between the GOG-218 and ICON7 trials and discusses when this research will start to impact on clinical practice. 10 Nov. 10Collected in Libby's H*O*P*E* Nov 10, 2010 -
ESMO 2010: The ICON7 Trial & Bevacizumab
Prof. Timothy Perren explains the results of the ICON7 trial investigating the use of bevacizumab to treat advanced ovarian cancer. This trial compared standard chemotherapy of carboplatin and paclitaxel with a treatment programme of carboplatin, paclitaxel and bevacizumab. Disease progression was found to be delayed and occurred less frequently in the bevacizumab group. Prof Perren discusses how representative the patient population was, considers the effect of residual disease status and outlines some ofCollected in Libby's H*O*P*E* Nov 4, 2010 -
2010 ESMO: Ovarian Cancer Responds to Bevacizumab - in Meeting Coverage, ESMO from MedPage Today
Women with high-risk early or advanced ovarian cancer gained almost two months in progression-free survival (PFS) when the angiogenesis inhibitor bevacizumab (Avastin) was added to chemotherapy, results of a large international clinical trial showed. 18 Oct. 10Collected in Libby's H*O*P*E* Oct 19, 2010 -
ASCO 2010: Ovarian Cancer Updates By Jennifer C. Obel, M.D.
Jennifer C. Obel, MD (NorthShore University Health System) discusses the latest ovarian cancer news at ASCO 2010. 28 Jul 10Collected in Libby's H*O*P*E* Jul 28, 2010 -
Key advances in ovarian cancer (ASCO 2010 )
Prof Jonathan Ledermann outlines some of the key advances in ovarian cancer that have been presented at ASCO 2010. Prof Ledermann discusses research demonstrating the effectiveness of combining bevacizumab with chemotherapy as first line treatment of ovarian cancer. A second key presentation was research indicating that PARP inhibitors are effective at treating not just ovarian cancer caused by BRCA mutation but also high grade serous cancer. If this result is confirmed in further studies, it would significCollected in Libby's H*O*P*E* Jul 22, 2010 -
Avastin & Potential Kidney Damage?
Avastin, a powerhouse cancer drug that has shown promise in fighting breast, colon, lung and even ovarian cancer, may also damage patients' kidneys, according to a study published Thursday in the Journal of the American Society of Nephrology. 11 Jun 10Collected in Libby's H*O*P*E* Jun 11, 2010 -
ASCO Cancer Drug Treatment Research Highlights Oncology Conference | PBS NewsHour | June 7, 2010 | PBS
Researchers reported new progress in the treatment of breast, skin, lung and ovarian cancers at a weekend meeting of top cancer experts in Chicago. Ray Suarez talks to American Society of Clinical Oncology President George Sledge for an update on the new medical advances. 08 Jun 10Collected in Libby's H*O*P*E* Jun 8, 2010 -
2010 ASCO: GOG-218 Avastin Study Results
Dr. Jennifer Obel talks about GOG 218 Avastin ovarian cancer study results presented at the 2010 ASCO Annual Meeting. For more information, visit Cancer.Net (http://www.cancer.net). 07 Jun 10Collected in Libby's H*O*P*E* Jun 7, 2010
Comments
Libby's H*O*P*E* (tm) "WORDs of Wisdom" video series: Dr. Bradley J. Monk explains the advantages and differences Avastin® has vs. other Ovarian Cancer treatment drugs, and how ovarian cancer patients may be able to access this treatment.Produced by: WORDonCancer.org (27 Jul 11)
Aug 16, 2011